Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Editas Medicine Inc EDIT

Healthcare Biotechnology
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid... see more

Current News (NDAQ:EDIT)

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

GlobeNewswire November 10, 2025

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

GlobeNewswire November 3, 2025

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

GlobeNewswire October 9, 2025

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

GlobeNewswire October 6, 2025

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

GlobeNewswire September 2, 2025

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

GlobeNewswire August 28, 2025

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire August 27, 2025

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

GlobeNewswire August 12, 2025

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

GlobeNewswire June 12, 2025
View More News ››

Opinion & Analysis (NDAQ:EDIT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EDIT)

RE:Ruby study expected to be completed Aug 2025

https://www.globenewswire.com/news-release/2020/12/05/2140152/0/en/CRISPR-Therapeutics-and-Vertex-Present-New-Data-for-Investigational...
Napcoo - May 21, 2024

Ruby study expected to be completed Aug 2025

 https://www.clinicaltrials.gov/study/NCT04853576
Napcoo - May 16, 2024

RE:Genome Therapy New Biotech Darling?

http://www.innovationnewsnetwork.com/crispr-technology-achieves-dna-repair-in-space-for-the-first-time/14184/
0checker - August 19, 2021

RE:Genome Therapy New Biotech Darling?

  Hi there, in the recent Jeff Brown pitch for his "exponential tech investor" he talks about a small cap biotech...
chiefmissile - December 27, 2020

Genome Therapy New Biotech Darling?

Just finished getting pitched Jeff Brown's newsletter for a small cap gene therapy company. I'm not sure which is his pick, but...
bcwildthing - November 3, 2020

1st Human Clinical Trial

When is this news going to be released? They said results would be a month and we are well past that. Any insight or idea when?
Kanoli - July 6, 2020
View more Bullboard ››

Equity Metals Corp.

Equity Metals Corp.

Equity Metals Corporation engages in the acquisition, exploration, and development of mineral and diamond properties in ...
View More »

Podcasts